Skip to main content
. 2022 Aug 11;6:e2200135. doi: 10.1200/PO.22.00135

FIG 3.

FIG 3.

(A) PFS and (B) OS in patients with amplified ERBB2 according to log2-converted ERBB2 CN class. Overall survival according to (C) high/low CN (cutoff 16) and (D) with/without coamplification genes other than ERBB2 in the HER2 signaling pathway. CN, copy number; ERBB2, erb-b2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; OS, overall survival; PFS, progression-free survival.